WebOct 5, 2024 · Statera Biopharma is developing therapies designed to elicit directly within patients a robust and durable response of antigen-specific killer T cells and antibodies, thereby activating essential... WebAug 31, 2024 · Cytocom, Inc. Nichol Ochsner Senior V.P. Investor Relations and Corporate Communications (732) 754-2545 [email protected] Tiberend Strategic …
Cytocom, Inc. Announces Plan to Adopt New Corporate Name …
WebStatera Biopharma is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. WebSep 28, 2024 · Cytocom issued the 125,000 shares of its common stock on March 4, 2024. Due to the fact that Cytocom did not have sufficient funds by January 25, 2024, it was unable to meet its payment obligations to Ira Gaines and the Gaines Trust due on that date. The $50,000 payment was made on June 9, 2024. how many on a team
VA Enterprise Information Management (EIM) Policy
WebApr 13, 2024 · Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. Statera has … WebStatera Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. Web--Cytocom, Inc., a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced plans to … how many oncogenes